Selpercatinib(LOXO-292) CAS 2152628-33-4 high quality can be supplied from stock
1 Inquiries
2152628-33-4
Pharmaceutical Grade
99%
Million
25kg/Cardboard Drum
Yes
2024-09-13
Apixaban Repotrectinib/TPX-0005,Edoxaban,Lurasidone,Elacestrant,Bexagliflozin,Baricitinib
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceSelpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers. Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.|Selpercatinib is a Kinase Inhibitor. The mechanism of action of selpercatinib is as a Rearranged during Transfection (RET) Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 3A Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor.|Selpercatinib is an orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.
Class: receptor tyrosine kinase; Treatment: RET-altered lung/thyroid cancers; Other name: ARRY-192, LOXO-292; Oral bioavailability = 73%; Elimination half-life = 32 h; Protein binding = 97%Basic Info-
Product Name:
Selpercatinib
Other Name:CPD2206;LOX-292;LOXO-292; LOXO292;LOXO 292;LOXO-292,Selpercatinib;Selpercatinib(LOXO-292);6-?(2-?Hydroxy-?2-?methylpropoxy)?-?4-?[6-?[6-?[(6-?methoxy-?3-?pyridinyl)?methyl]?-?3,?6-?diazabicyclo[3.1.1]?hept-?3-?yl]?-?3-?pyridinyl]?pyrazolo[1,?5-?a]?pyridine-?3-?carbonitrile;Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]-;LOXO-292 USP/EP/BP
CAS No.:2152628-33-4
Molecular Formula:C29H31N7O3
InChIKeys:XIIOFHFUYBLOLW-UHFFFAOYSA-N
Molecular Weight:525.6
Exact Mass:525.24883788
EC Number:207-854-9
UNII:CEGM9YBNGD
NCI Thesaurus Code:C134987
Color/Form:White to off-white
ATC Code:L01EX22
Categories:
Characteristics-
Density:
1.36±0.1 g/cm3(Predicted)
Water Solubility:<1 mg/mL
PKA:14.00±0.29(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Apixaban Repotrectinib/TPX-0005,Edoxaban,Lurasidone,Elacestrant,Bexagliflozin,Baricitinib
-
Location:
Room1-2208,Lianhecaifu Square,No2177,Tianchen road,Gaoxin district
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
3 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2012
Company Certificates-
certification of high-tech enterprise
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
Pakistan
Selpercatinib
500 MG Jun 24, 2025 Post an enquiry for this product
More from this Seller
-
-
![Lurasidone CAS 367514-87-2 high quality can be supplied from stock]( "Lurasidone CAS 367514-87-2 high quality can be supplied from stock")
-
Lurasidone CAS 367514-87-2 high quality can be supplied from stock
Pharmaceutical Grade / 99%
-
-
-
![Bexagliflozin CAS 1118567-05-7 high quality can be supplied from stock]( "Bexagliflozin CAS 1118567-05-7 high quality can be supplied from stock")
-
Bexagliflozin CAS 1118567-05-7 high quality can be supplied from stock
Pharmaceutical Grade / 99%
-
-
-
![Apixaban CAS 503612-47-3 high quality can be supplied from stock]( "Apixaban CAS 503612-47-3 high quality can be supplied from stock")
-
Apixaban CAS 503612-47-3 high quality can be supplied from stock
Pharmaceutical Grade / 99%
-
-
-
![Elacestrant dihydrochloride CAS 1349723-93-8 high quality can be supplied from stock]( "Elacestrant dihydrochloride CAS 1349723-93-8 high quality can be supplied from stock")
-
Elacestrant dihydrochloride CAS 1349723-93-8 high quality can be supplied from stock
Pharmaceutical Grade / 99%
-
-
-
![Ziprasidone hydrochloride monohydrate CAS 138982-67-9 high quality can be supplied from stock]( "Ziprasidone hydrochloride monohydrate CAS 138982-67-9 high quality can be supplied from stock")
-
Ziprasidone hydrochloride monohydrate CAS 138982-67-9 high quality can be supplied from stock
Pharmaceutical Grade / 99%
-
-
-
![ROPSACITINIB/PF-06826647 CAS 2127109-84-4 good quality large supply fast delivery best service]( "ROPSACITINIB/PF-06826647 CAS 2127109-84-4 good quality large supply fast delivery best service")
-
ROPSACITINIB/PF-06826647 CAS 2127109-84-4 good quality large supply fast delivery best service
Pharmaceutical Grade / 99%
-
